Aspire Biopharma Holdings completed its acquisition of Dura Driver Control Systems (DCS) for approximately $30 million in cash and entered into a $22.5 million senior secured revolving credit facility to fund the transaction. The company also issued convertible promissory notes with an aggregate principal amount of $3,750,000 for a purchase price of $3,000,000, reflecting a 20% original issue discount, to provide working capital. DCS generated approximately $209.5 million in revenue and $22.3 million in Adjusted EBITDA for the twelve months ended December 31, 2025. Aspire Biopharma Holdings operates in the biotechnology industry, developing patent-pending sublingual drug delivery technologies.

Aspire Biopharma Holdings, Inc. clarified the terms of its public warrants (ASBPW) following two previous reverse stock splits. A 1-for-30 reverse split occurred on January 16, 2026, and a 40-1 reverse split occurred on May 11, 2026. Consequently, the warrants now have an exercise price of $13,800 per share and a conversion ratio of 1,200 warrants to purchase one share of common stock. The company operates in the biopharmaceutical industry, focusing on the development of therapeutic drugs.